Seoul, South Korea

Tae Sup Lee

USPTO Granted Patents = 1 



Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tae Sup Lee: Innovator in Monoclonal Antibodies

Introduction

Tae Sup Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies for cancer treatment. His innovative work has the potential to impact cancer therapies significantly.

Latest Patents

One of Tae Sup Lee's notable patents is for "Humanized anti-tag-72 monoclonal antibodies." This invention relates to humanized antibodies that are specific to a tumor-associated glycoprotein known as TAG-72. The patent details a humanized antibody that has enhanced antigen binding affinity achieved by mutating a heavy chain of a humanized antibody PXA/HzK specific for TAG-72. Additionally, the invention includes anticancer compositions that comprise these humanized antibodies.

Career Highlights

Tae Sup Lee is affiliated with the Korea Research Institute of Bioscience and Biotechnology. His work at this esteemed institution has allowed him to focus on groundbreaking research in the field of monoclonal antibodies. His dedication to advancing cancer treatment through innovative solutions is commendable.

Collaborations

Tae Sup Lee has collaborated with notable colleagues, including Hyo Jeong Hong and Sang Jick Kim. These partnerships have fostered a collaborative environment that enhances research and development in their field.

Conclusion

Tae Sup Lee's contributions to the development of humanized antibodies represent a significant advancement in cancer treatment. His innovative spirit and dedication to research continue to inspire progress in biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…